Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02782858 | Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS | PHASE2 | COMPLETED | 270 | — | — | Apr 1, 2016 | Dec 1, 2017 | Oct 20, 2020 | 12 | Bulgaria, Croatia +10 |
| Arm | Type | Description |
|---|---|---|
| Dose 1 GNbAC1 | EXPERIMENTAL | Monthly IV repeated dose |
| Dose 2 GNbAC1 | EXPERIMENTAL | Monthly IV repeated dose |
| Dose 3 GNbAC1 | EXPERIMENTAL | Monthly IV repeated dose |
| Placebo | PLACEBO_COMPARATOR | Monthly IV repeated dose |
| Name | Type | Description |
|---|---|---|
| GNbAC1 | DRUG | Monthly IV repeated dose |
| Placebo | DRUG | Monthly IV repeated dose |
Main Inclusion Criteria: * For male or female with reproductive potential, use of reliable means of contraception; * RRMS according to the 2010 revised McDonald criteria; * Disease activity characterised by at least one documented relapse within the last 12 months and /or at least one Gd-enhancing ...